The evidence base about post‒COVID-19 condition, also known as long COVID, is emerging. Its long-term effects on people and health systems are uncertain; but based on the latest estimates, hundreds of thousands of people in Canada and millions of people around the world may be affected. As the evidence base continues to evolve, the purpose of this Horizon Scan is to provide health care decision-makers in Canada with an awareness about:
This Horizon Scanning report summarizes information regarding an emerging health technology — a wearable respiratory sensor for the detection of opioid-induced respiratory depression.
Horizon Scan reports provide brief summaries of information regarding new and emerging health technologies. These technologies are identified through the Canada's Drug Agency Horizon Scanning Service as topics of potential interest to health care decision-makers in Canada.
This Horizon Scan summarizes the available information regarding an emerging technology, Barricaid — a spinal implant device for those at risk of recurrent spinal disc herniation.
Horizon Scan reports provide brief summaries of information regarding new and emerging health technologies. These technologies are identified through the Canada's Drug Agency Horizon Scanning Service as topics of potential interest to health care decision-makers in Canada.
This Horizon Scan summarizes the available information regarding an emerging technology, Phagenyx, a pharyngeal electrical stimulation device for the treatment of dysphagia associated with neurologic conditions.
A growing evidence base suggests that autologous hematopoietic stem cell transplantation (AHSCT) is a clinically effective emerging intervention for select people with aggressive or highly active relapse-remitting multiple sclerosis (MS) who experience limited disease control with disease-modifying therapies.
The purpose of this report is to provide an overview of virtual visits in Canada — including a description of how virtual visits are delivered and how virtual visits are used — including potential benefits and challenges. Direct-to-patient virtual visits have the potential to change and potentially improve the delivery of health care in Canada. However, there are unresolved issues related to standards, licensure, equity, quality care provision, payment, and medical education that need to be addressed to prepare for a post‒COVID-19 health care system that includes virtual visits.
Drugs for rare diseases (DRD) can address significant unmet therapeutic needs for patients living with seriously debilitating and life-threatening conditions; however, the high costs of these drugs can pose challenges for public drug programs and health care systems.
There are several challenges with the application of standard health technology assessment methods for the assessment of DRD. To address these challenges, agencies and public payers have established separate or modified processes and programs to review and make reimbursement recommendations for DRD.
The Canada's Drug Agency Horizon Scanning Service identifies and monitors new and emerging health technologies with the potential to have a significant impact on health care in Canada. This List of 2021 Health Technology Trends to Watch focuses on those categories of medical devices, clinical interventions, or other health technologies that are, or may become, important or disruptive to Canadian health care or decision-making in the next few years.
This report presents an overview of an emerging health technology, a description of some of the published clinical studies, and a summary of some important considerations related to the potential implementation of technology. This report was not prepared using systematic review methods and did not involve critical appraisal or analysis of relevant study findings. This report is not intended to provide recommendations for or against the use of a particular technology.